- Rheumatologie-App Injektionstechnik
- Neue Studien
- Kongress Highlights
- EULAR 2019
- EULAR 2018
- EULAR 2017
- EULAR 2016
- EULAR 2015
- EULAR 2014
- ACR 2019
- ACR 2018
- ACR 2017
- ACR 2015
- ACR 2014
- Rheuma Top 2019
- Rheuma Top 2018
- Rheuma Top 2017
- Rheuma Top 2015
- Rheuma Top 2014
- Bilddatenbank
- RheumaTool
- SlideSet RA
- SlideSetSpA
- SonoTool
- FOCUS «Der Fuss»
- FOCUS «Die Hand»
- FOCUS «Kinderrheuma»
- EisenPaket
- LupusPaket
- OsteoPaket
- Publikationen
- Literaturservice
- Richtlinien
- Schmerzpaket
- Immunotalk
ACR 2019 | Daily Highlights
Biologics and malignancies
RISK OF MALIGNANCIES ASSOCIATED WITH BIOLOGICS IN RHEUMATOID ARTHRITIS: ANALYSIS OF A NATIONAL CLAIM DATABASE
Abstract: 849
Authors: Raphaèle Seror et al.
Key content:
European centralized insurances offer the possibility to analyze the safety of new therapies in a population-based fashion. This work analyzed over 80’000 rheumatoid arthritis (RA) patients in the French «Sécurité Social» and compared the incidence of new malignancies between biologic and csDMARD-treated RA patients. The overall risk of malignancies, the risk of solid cancer (excluding non-melanoma skin cancer), the risk of lymphoma and other hematologic malignancies, did not differ significantly between csDMARD and all biologics analyzed together. Regarding organ specific cancer, no difference was observed, except for risk of prostate cancer in men that occurred significantly less frequently in biologic treated patients (HR: 0.47 [0.29;0.76], p=0.003).
Relevance:
Confirming previous results from registries, this analysis of a large representative nationwide healthcare database, the overall risk of malignancies in biologic treated RA patients did not differ from that of patients treated with csDMARD. Interestingly prostate cancer in men occurred less frequently in biologics treated patients, which could be linked to better screening before introducing biologic. Overall, these results are reassuring concerning the risk of cancer with bDMARDs.
Zusammenfassung und Kommentar von:
Prof. Dr. Axel Finckh
Genf
